Rebecca F. Gottesman, MD, PhD; Andrea L. C. Schneider, MD, PhD; Marilyn Albert, PhD; et al.
free access
JAMA Neurol. 2014;71(10):1218-1227. doi:10.1001/jamaneurol.2014.1646
Gottesman et al evaluate the association between midlife (48-67 years of age) hypertension and the 20-year change in cognitive performance among the Atherosclerosis Risk in Communities cohort. See also the editorial by Gorelick.
Angel C. Y. Mak, PhD; Clive R. Pullinger, PhD; Ling Fung Tang, PhD; et al.
free access
JAMA Neurol. 2014;71(10):1228-1236. doi:10.1001/jamaneurol.2014.2011
Mak et al describe a man with extensive tuberous and morbilliform cutaneous xanthomas and exceptionally severe dysbetalipoproteinemia. They aimed to discover the molecular basis of the disorder and to determine the effects of complete absence of apolipoprotein E on neurocognitive and visual function and on lipoprotein metabolism. Lane-Donovan and Herz provide commentary in a related editorial.
Brent L. Fogel, MD, PhD; Hane Lee, PhD; Joshua L. Deignan, PhD; et al.
free access
JAMA Neurol. 2014;71(10):1237-1246. doi:10.1001/jamaneurol.2014.1944
Fogel and colleagues investigated the contribution of genetic disease in a population of patients with predominantly adult- and sporadic-onset cerebellar ataxia. Gomez and Das provided a related .
-
Editorial
Clinical Exome Sequencing: The New Standard in Genetic Diagnosis
Christopher M. Gomez, MD, PhD; Soma Das, PhD
JAMA Neurol
Kevin S. King, MD; Julia Kozlitina, PhD; Roger N. Rosenberg, MD; et al.
free access
JAMA Neurol. 2014;71(10):1247-1254. doi:10.1001/jamaneurol.2014.1926
King et al determine if peripheral blood telomere length is associated with brain volume. Peripheral blood leukocyte telomere length and brain volumes were measured among 1950 individuals (median age, 50 years) in the Dallas Heart Study. Global and 48 regional brain volumes were assessed from the automated analysis of magnetic resonance imaging.
Juan M. Pascual, MD, PhD; Peiying Liu, PhD; Deng Mao, BS; et al.
free access
JAMA Neurol. 2014;71(10):1255-1265. doi:10.1001/jamaneurol.2014.1584
Pascual et al evaluate the use of triheptanoin in the treatment of glucose transporter type I deficiency in a case series including 14 patients.
Dominic Holland, PhD; Linda Chang, MD; Thomas M. Ernst, PhD; et al.
free access
JAMA Neurol. 2014;71(10):1266-1274. doi:10.1001/jamaneurol.2014.1638
Holland et al assessed structural growth trajectories and rates of change in the whole brain and regions of interest in infants during the first 3 months after birth.
Olga Marshall, MS; Hanzhang Lu, PhD; Jean-Christophe Brisset, PhD; et al.
free access
JAMA Neurol. 2014;71(10):1275-1281. doi:10.1001/jamaneurol.2014.1668
Marshall and coauthors use hypercapnic perfusion magnetic resonance imaging to assess cerebrovascular reactivity impairment in patients with multiple sclerosis.
Sebastian Palmqvist, MD, PhD; Henrik Zetterberg, MD, PhD; Kaj Blennow, MD, PhD; et al.
free access
JAMA Neurol. 2014;71(10):1282-1289. doi:10.1001/jamaneurol.2014.1358
Palmqvist and colleagues studied whether cerebrospinal fluid (CSF) biomarkers, analyzed consecutively in routine clinical practice during 2 years, can predict cortical 尾-amyloid (A尾) deposition, and aimed to establish a threshold for A尾42 abnormality.
Michael R. DeLong, BA; Kevin T. Huang, AB; John Gallis, ScM; et al.
free access
has audio
JAMA Neurol. 2014;71(10):1290-1295. doi:10.1001/jamaneurol.2014.1272
DeLong et al suggest that age alone should not be a primary exclusion factor for determining candidacy for deep brain stimulation. Instead, a clear focus on patients with medication-refractory and difficult to control on-off fluctuations with preserved cognition, regardless of age, may allow for an expansion of the traditional therapeutic window.
-
Podcast:
Effect of Advancing Age on Outcomes of Deep Brain Stimulation for Parkinson Disease